Score Overview
Explore the 2021 public Archive ranking →
Where Lipocine Inc has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. LPCN does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-22 | $ 1.46 | — |
1 Year2025-10-22 | $ 2.81 | -48.04% |
5 Years2021-10-22 | $ 18.02 | -91.90% |
10 Years2016-10-21 | $ 60.86 | -97.60% |
All Time2013-10-22 | $ 170.00 | -99.14% |
| Period | Last Price2026-10-22 | 1 Year2025-10-22 | 5 Years2021-10-22 | 10 Years2016-10-21 | All Time2013-10-22 |
|---|---|---|---|---|---|
| Price | $ 1.46 | $ 2.81 | $ 18.02 | $ 60.86 | $ 170.00 |
| Return | — | -48.04% | -91.90% | -97.60% | -99.14% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 1M | -$ 11M | $ 23M |
| 2025 | $ 1M | -$ 9M | $ 14M |
| 2024 | $ 11M | $ 21M | |
| 2023 | -$ 2M | -$ 16M | $ 22M |
| 2022 | $ 500K | -$ 10M | $ 32M |
| 2021 | $ 16M | -$ 634.4K | $ 44M |
| 2020 | $ 0.00 | -$ 20M | $ 19M |
| 2019 | $ 164.99K | -$ 13M | $ 14M |
| 2018 | $ 428.03K | -$ 11M | $ 15M |
| 2017 | $ 0.00 | -$ 20M | $ 21M |
| 2016 | $ 0.00 | -$ 18M | $ 26M |
| 2015 | $ 0.00 | -$ 18M | $ 44M |
| 2014 | $ 0.00 | -$ 20M | $ 27M |
| IPO2013 | $ 0.00 | -$ 10M | $ 45M |
Lipocine Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 0.00 to $ 1M and net income went from -$ 20M to -$ 9M. Revenue increased in 1 of those 5 years; net income in 0.
Lipocine Inc currently holds a 5-year HDB Score of 0.7 out of 10. How the HDB Score is calculated.
Membership
Explore LPCN with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,119 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
Explore other companies
Co-Diagnostics, Inc. Common StockCODX· revenue grew in 20% of years
Inhibikase Therapeutics IncIKT· revenue grew in 20% of years
Xenon Pharmaceuticals IncXENE· revenue grew in 20% of years
Revolution Medicines IncRVMD· revenue grew in 20% of years
Solid Biosciences LLCSLDB· revenue grew in 0% of years
